Increased Ratio of Matrix Metalloproteinase-9 (MMP-9)/Tissue Inhibitor Metalloproteinase-1 from Alveolar Macrophages in Chronic Asthma with a Fast Decline in FEV at 5-Year Follow-up.

Chronic asthma is associated with progressive airway remodeling, which may contribute to declining lung function. An increase in matrix metalloproteinases-9 (MMP-9)/tissue inhibitor metalloproteinase-1 (TIMP-1) may indicate airway inflammation and bronchial injury. Bronchial biopsy specimens and alveolar macrophages (AMs) were obtained from patients with asthma under regular treatment with inhaled corticosteroids or combination therapy and normal subjects ( = 10). Asthmatics included those with a slow forced expiratory volume in one second (FEV) decline (<30 mL/year, = 13) and those with a fast FEV decline (≥30 mL/year, = 8) in 5-year follow-up. Immunostaining expression of MMP-9 and TIMP-1 was detected in airway tissues. MMP-9 and TIMP-1 was measured from AMs cultured for 24 h. After the 5-year treatment, the methacholine airway hyperresponsiveness of the slow FEV decline group was decreased, but that of the fast FEV decline group was increased (PC, provocative concentration causing a 20% decrease in FEV, 3.12 ± 1.10 to 1.14 ± 0.34 mg/dL, < 0.05). AMs of asthma with a fast FEV decline released a higher level of MMP-9 (8.52 ± 3.53 pg/mL, < 0.05) than those of a slow FEV decline (0.99 ± 0.20 pg/mL). The MMP-9/TIMP ratio in the fast FEV decline group (0.089 ± 0.032) was higher than that of the slow FEV decline group (0.007 ± 0.001, < 0.01). The annual FEV decline in 5 years was proportional to the level of MMP-9 (r = 57, < 0.01) and MMP-9/TIMP-1 ratio (r = 0.58, < 0.01). The airways of asthma with greater yearly decline in FEV showed an increased thickness of submucosa and strong expression of MMP-9. An increase in MMP-9 and MMP-9/TIMP-1 in airways or AMs could be indicators of chronic airway inflammation and contribute to a greater decline in lung function of patients with chronic asthma.